These data evidently suggest that specific elimination of EREG from the whole spectrum of SASP in a treatment-damaged TME enhances tumor response to chemotherapy, a process independent of androgen regulation or AR signaling of prostate tumors per se. The gene discussed is AR; the disease is neoplasm.